Novel mutations in African American patients with glycogen storage disease type II

Nina Raben(APT Therapeutics (United States)), Paul H. Plötz(National Institutes of Health), Laura Lee(National Institutes of Health), Eunice Lee(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Rochelle Hirschhorn(New York University)
Human Mutation
January 1, 1999
10.1002/(sici)1098-1004(1999)13:1<83::aid-humu13>3.0.co;2-2
Cited by 15

Related Papers

Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus Erythematosus
|New England Journal of Medicine|1979|531
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
|The Journal of Experimental Medicine|2005|395
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
|Lara D. Veeken|2003|367